According
to The Gray Sheet’s recent MDMA reimbursement
panel coverage, physician specialty societies are
gaining influence over reimbursement policies. And
yet, it’s no longer acceptable for device manufacturers
to “lobby” AMA advisory panel members
about proposed CPT code changes.
Nevertheless,
manufacturers shouldn’t hesitate to gain support
for their technologies by engaging specialty societies
in other, more appropriate ways. That was the advice
of panel member and JR Associates President, Judy
Rosenbloom.
Rosenbloom
encouraged manufacturers to recognize that each
specialty society has different structures and processes.
She recommended that they focus on “introducing
the company, the device, and its value in a very
‘non-asking’ way, so-to-speak.”
After
the initial introduction, follow-up can involve
asking for a society’s support on a coding
application, she said. This helps reveal who’s
responsible – an advocacy group, or an individual
physician.
The
article features illustrations of societies’
growing influence over coverage and payment. In
addition, commentary is included from other panel
members – Jo Ellen Slurzberg of Almryra, and
John McInnes, MD, a partner at the law firm of Arnold
& Porter.
THE
GRAY SHEET
Specialty
Societies Increasingly Hold Key to Reimbursement,
Insiders Say
November
12, 2007
Vol.
33, No. 047, Page 15
To
read the full article, visit The Gray Sheet on the
web at
http://www.thegraysheet.com
